These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36820147)

  • 1. The Comprehensive Role of High Mobility Group Box 1 (HMGB1) Protein in Different Tumors: A Pan-Cancer Analysis.
    Guan H; Zhong M; Ma K; Tang C; Wang X; Ouyang M; Qin R; Chen J; Zhu E; Zhu T; Lu Y; Liu Y; Tian C; Zheng Z
    J Inflamm Res; 2023; 16():617-637. PubMed ID: 36820147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].
    Wang H; Li W; Zhang D
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Apr; 42(4):473-485. PubMed ID: 35527483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-cancer analysis of trophinin-associated protein with potential implications in clinical significance, prognosis, and tumor microenvironment in human cancers.
    Li Z; Pu Z; Yang Z; Zhu Y; Deng Y; Li N; Peng F
    Front Oncol; 2022; 12():971618. PubMed ID: 36419876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis.
    Zhang QB; Jia QA; Wang H; Hu CX; Sun D; Jiang RD; Zhang ZL
    BMC Cancer; 2016 Nov; 16(1):880. PubMed ID: 27836008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 8. A systematic analysis of
    Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
    Front Genet; 2022; 13():926943. PubMed ID: 35991552
    [No Abstract]   [Full Text] [Related]  

  • 9. Exploring the immunological role and prognostic potential of PPM1M in pan-cancer.
    Zeng R; Wang L; Zhang Y; Yang Y; Yang J; Qin Y
    Medicine (Baltimore); 2023 Mar; 102(12):e32758. PubMed ID: 36961170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
    Xiao Y; Sun L; Fu Y; Huang Y; Zhou R; Hu X; Zhou P; Quan J; Li N; Fan XG
    BMC Cancer; 2017 Dec; 17(1):857. PubMed ID: 29246127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 13. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
    Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
    Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
    [No Abstract]   [Full Text] [Related]  

  • 14. Systematic pan-cancer analysis identifies
    Chen P; Yang X; Wang P; He H; Chen Y; Yu L; Fang H; Wang F; Huang Z
    Ann Transl Med; 2023 Jan; 11(2):121. PubMed ID: 36819495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration.
    Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q
    Front Oncol; 2022; 12():998336. PubMed ID: 36185230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
    Liu C; Zhang W; Zhou X; Liu L
    Front Immunol; 2022; 13():983490. PubMed ID: 36618420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
    Li L; Wang X; Ding Y; Hui N; Su B; Yang M
    Eur J Med Res; 2022 Oct; 27(1):216. PubMed ID: 36307879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic pan-cancer analysis of the nicotinamide n-methyltransferase in human cancer.
    Cao L; Wu W; Deng X; Peng Y; Chen Y; Guo H; Wang L; Li X; Zhang Z; Shao Z
    Front Genet; 2022; 13():1000515. PubMed ID: 36386816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.